(2003) Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. The Breast 12 , 457-471 /Silverstein, MJ, Buchanan, C (2003) Ductal carcinoma in situ: USC/Van Nuys prognostic inde
Ductal carcinoma in situ of the breast: a surgeon's disease. Ann Surg Oncol. 1999;6:802- 810.Silverstein M.J. Ductal carcinoma in situ of the breast: a surgeon's dis- ease. Ann Surg Oncol, 1999, 6: 802- 810.Silverstein MJ. Ductal carcinoma in situ of the breast: A sur- geon'...
In: Ductal Carcinoma In Situ of The Breast, MJ Silverstein, ed. Williams & Wilkins, Baltimore, MD, pp. 39–42 Allred DC, Bryant J, Dignam JJ, et al (2002) Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP ...
These findings are reassuring for both patients and physicians in the context of decision making about treatment options. Bober SL, A Giobbie-Hurder, Emmons KM, Winer E, and Partridge A. Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med **;...
Invasive ductal carcinoma (IDC), the most common type of breast cancer in the U.S., starts in your milk ducts and spreads to nearby tissue. Like IDC, ductal carcinoma in situ (DCIS) starts in your milk ducts, but it does not spread outside the duct walls. Treatment for IDC and DCIS...
Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol. 2002;26:56–63. Article PubMed Google Scholar Ayars M, Eshleman J, Goggins M. Susceptibility of ATM-deficient pancreatic cancer...
It is thought that equal numbers of invasive and noninvasive recurrences develop after conservative treatment for ductal carcinoma in situ. We analyzed our data to see if this was true. Evidence Ranking: E Expert Rating: 1 To access this article, please choose from the options below Log In Em...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer (IBC). Studies have indicated differences in DCIS outcome based on race or ethnicity, but molecular differences have not been investigated. We examined the molecular pr
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in
Ductal carcinoma in situ rate among abnormal screen-detected mammographies reached 13.8%. Ductal carcinoma in situ is treated by mastectomy or conservative surgery (CS) with or without radiotherapy (RT) (Morrow et al, 2002; Ceilley et al, 2004; Mokbel and Cutuli, 2006). The best option ...